Request Sample Inquiry
Cancer Pain Market

Cancer Pain Market

Cancer Pain Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

195

Base Year:

2023

Date

Jun - 2024

Format:

PDF XLS PPT

Report Code:

VMR-2505

Segments Covered
  • By Drug Type By Drug Type Opioids, Non-Opioids, Nerve Blockers
  • By Disease Indication By Disease Indication Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Other Disease Indications
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 7.39 Billion
Revenue 2032Revenue 2032: USD 11.86 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 5.4%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Asia Pacific
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
Cancer Pain Market Share

The global Cancer Pain Market is valued at USD 7.39 Billion in 2023 and is projected to reach a value of USD 11.86 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 5.4% between 2024 and 2032.

Key highlights of Cancer Pain Market

  • The North American region accounted for 35.5% of the revenue market in 2023,
  • The Asia Pacific region is poised for significant expansion, anticipated to witness remarkable growth with a notable CAGR throughout the forecast period,
  • The Opioids segment emerged as the frontrunner in the cancer pain market in 2023, commanding a substantial market share of 54.2%, consolidating their position as the leading therapeutic choice,
  • The Lung cancer emerged as the predominant segment in the market in 2023, capturing a substantial market share of 26.5%, underscoring its prominence within the Cancer Pain landscape,
  • The emergence of personalized medicine and precision treatment strategies is revolutionizing the Cancer Pain market.

Cancer Pain Market Size, 2023 To 2032 (USD Billion)

AI (GPT) is here !!! Ask questions about Cancer Pain Market
Loading....

Cancer Pain Market: Regional Overview

North America Dominated Sales with a 35.5% share in 2023. North America's prominence in the Cancer Pain market is driven by its advanced healthcare infrastructure, widespread availability of pain management therapies, and the prevalence of cancer-related pain cases across the region. North America leads the industry in both pain management and oncology research because to its leading pharmaceutical companies and academic institutions.

The United States and Canada play pivotal roles in propelling the growth of the Cancer Pain market in North America driven by prevalence of cancer in the countries. For instance, the Canadian cancer Society (CCS) stated approximately 29,800 Canadians recognized with lung cancer in 2020, representing 13% of all new cancer cases, with an estimated 21,200 deaths, comprising 25% of all cancer-associated deaths.

The U.S. and Canada boasts well-established healthcare systems with robust reimbursement policies, facilitating patient access to a broad range of pain management medications and treatments. Initiatives to improve pain treatment techniques and increase public awareness of cancer pain also aid in the market's growth. Options for cancer pain treatment and care in the area are also improved by cooperative efforts between advocacy organizations, policymakers, and healthcare professionals.

The region's market presence will be further strengthened by ongoing investments in R&D, developments in pain management technology, and an increasing focus on personalized medicine techniques. For instance, President Biden's FY26 budget providing .9 billion funding for cancer research and prevention, aligning with the goal of the Cancer Moonshot initiative. Furthermore, it's anticipated that proactive regulatory frameworks and continuing efforts to handle opioid-related issues while guaranteeing access to efficient pain relief solutions will promote market expansion and innovation in North America.

U.S. Cancer Pain Market Overview

The U.S. Cancer Pain market, valued at USD 1.57 Billion in 2023 to USD 2.4 Billion in 2032, is anticipated to grow at a CAGR of 4.9% from 2024 to 2032.

According to the data from the National Cancer Institute, up to 50 percent of cancer patients encounter pain, with approximately 80 percent of those in advanced stages of the disease enduring pain ranging from moderate to severe. The United States market represents a crucial component of the broader healthcare landscape, characterized by a comprehensive approach to pain management and oncology care.

With a high prevalence of cancer cases and a growing population of cancer survivors, the demand for effective pain relief solutions remains paramount. For instance, according to the American Cancer Society journal, approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths are projected in the United States for the year 2023.

The U.S. healthcare system emphasizes personalized treatment approaches, driving innovation and advancements in cancer pain management. Healthcare providers leverage a wide range of pharmaceuticals, interventional procedures, and supportive therapies to address the multifaceted nature of cancer pain, striving to enhance patient quality of life and overall treatment outcomes.

Pharmaceutical companies continuously strive to introduce novel pain medications and therapies, aiming to address the evolving needs of cancer patients while adhering to stringent regulatory standards. Additionally, collaborative efforts between healthcare institutions, academic centers, and advocacy groups contribute to raising awareness about cancer pain management strategies and fostering a holistic approach to patient care.

Cancer Pain Market: Drug Type Overview

The Opioids segment dominated the Cancer Pain market with the largest share of 54.2% in 2023. The Cancer Pain market, segmented by the Drug Type, is bifurcated into Opioids, Non-Opioids, Nerve Blockers.

Opioids have traditionally played a central role in alleviating pain associated with cancer. Opioids act on the central nervous system to modulate pain signals, providing effective relief for moderate to severe pain. Due to their potency and efficacy, opioids have long been the cornerstone of pharmacological therapy for cancer pain. Because they have an established record of quickly and effectively relieving pain, opioids are still frequently recommended for cancer pain management despite worries about abuse, addiction, and side effects.

According to the WHO international guidelines, opioid pain relievers stand as the predominant treatment for managing cancer-related pain. These guidelines support the use of opioid drugs to effectively treat cancer pain, including the ongoing background pain and the intermittent flare-ups known as breakthrough cancer pain.

Opioids, also known as narcotics, are prescribed by healthcare professionals to alleviate severe pain associated with various conditions, including cancer, surgery recovery, and acute injuries. Common opioid medications include codeine, fentanyl, oxycodone, and morphine, which are often marketed under brand names such as OxyCotin, Percocet, Palladone, and Vicodin. Even though opioids are useful in treating pain, there is increasing concerned about their abuse and addiction. This has led to stricter regulations and the creation of formulations that are less probable to be abused.

The emergence of novel therapies and innovative drug delivery systems holds promise for transforming cancer pain management. Targeted therapies, such as gene therapies, immunotherapies, and monoclonal antibodies, are being investigated for their potential to reduce pain associated with cancer by focusing on particular molecular pathways that are implicated in inflammation and pain signaling. The Cancer Pain market is expected to experience additional innovation and evolution in medication type offerings as long as research and development efforts in the fields of oncology and pain management continue to progress.

Cancer Pain Market: Government Initiatives

  • The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) is a significant health insurance scheme in India that provides coverage of up to INR 5 lakhs per family per year. This insurance extends to both secondary and tertiary care hospitalization expenses, encompassing a wide range of medical treatments, including those related to cancer.
  • The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) is a government initiative focused on combating chronic non-communicable diseases, including cancer. NPCDCS adopts a multi-faceted approach to disease management, emphasizing prevention, early detection, and treatment. By implementing targeted interventions such as awareness campaigns, screening programs, and access to affordable treatment options, NPCDCS aims to reduce the incidence and impact of cancer and other non-communicable diseases across India.
  • The Rashtriya Arogya Nidhi (RAN) is a critical initiative aimed at providing financial assistance to economically disadvantaged patients suffering from life-threatening diseases, including cancer. RAN enables patients below the poverty line to access medical treatment at government hospitals, ensuring that they receive necessary care without financial barriers.
  • In March 20, 2020, the Production Linked Incentive (PLI) Scheme for Promoting Domestic Manufacturing of Medical Devices boasts a total financial outlay of Rs. 3,420 crore. This initiative targets four specific segments within the medical device industry: cancer care and radiotherapy medical devices; radiology and imaging medical devices including nuclear imaging devices; anesthetics and cardio-respiratory medical devices; and renal care medical devices along with all implants, including implantable electronic devices.
  • In efforts to advance research in Ayurveda for cancer treatment, the Government has implemented various measures. The Central Council for Research in Ayurvedic Sciences (CCRAS), established as an autonomous organization by the Government, is actively engaged in research pertaining to Cancer. Additionally, CCRAS plays a pivotal role in drug development and documentation of medical practices, with a specific focus on improving the quality of life for cancer patients through initiatives such as the development of AYUSH QOL2C. This holistic approach aims to enhance the overall well-being and treatment outcomes for individuals battling cancer.
  • The Canadian Pain Task Force (CPTF) was instituted with the aim of offering guidance and insights to Health Canada, aimed at enhancing the strategies for preventing and managing chronic pain across the nation. In January 2023, the mandate of the CPTF was revitalized and expedited to provide recommendations on priority actions, with a primary focus on acknowledging and supporting individuals grappling with pain, while also emphasizing the necessity to understand, prevent, and effectively address pain throughout Canada.
  • In 2022, the U.S. Department of Health and Human Services, in collaboration with the Centers for Medicare & Medicaid Services (CMS), introduced a novel model geared towards enhancing cancer care for Medicare beneficiaries while also aiming to reduce healthcare expenditures. Designed by CMS’ Center for Medicare and Medicaid Innovation (Innovation Center), the Enhancing Oncology Model (EOM) seeks to assess methods for augmenting healthcare providers' capacity to provide patient-centered care, accommodate individual patient requirements, and administer cancer treatment strategies conducive to optimizing patient outcomes.
  • In 2024, the Health Resources and Services Administration (HRSA) is bolstering its Accelerating Cancer Screening (AxCS) Initiative with an additional investment of $10 million to bolster the Alcee L. Hastings Program for Advanced Cancer Screening, raising the total program funding to over $25 million within three years.

Key Trends

  • The Cancer Pain market is witnessing significant advancements in pain management therapies, including the development of new analgesics, targeted therapies, and non-pharmacological approaches, is being observed in the Cancer Pain market. These developments are intended to minimize adverse effects and enhance quality of life for cancer patients by offering more efficient and customized pain treatment solutions.
  • Personalized medicine approaches are gaining traction in the Cancer Pain market. These approaches seek to tailor pain management plans to each patient's unique features, such as genetic makeup, tumor biology, and pain phenotypes. Pain management therapies can be optimized for better patient outcomes and efficacy by healthcare practitioners by utilizing biomarkers and precision medicine technologies.
  • In order to improve pain evaluation, monitoring, and therapy in the Cancer Pain industry, technology is essential. Wearable technology, telemedicine platforms, smartphone apps, and electronic health records (EHRs) are examples of innovations that allow for real-time communication between patients and healthcare professionals, remote monitoring of pain symptoms, and data-driven decision-making to maximize pain management techniques.

Premium Insights

According to NIH, each year, over 10 million individuals globally face a diagnosis of cancer, with pain emerging as a significant issue accompanying their condition. While not universal, pain remains a prevalent experience among cancer patients. Additionally, during active cancer treatment, approximately one-third of adults and two-thirds of those in advanced stages of the disease encounter pain. Similarly, children undergoing cancer treatment also endure similar pain experiences. So, the growing demand for cancer treatment serves as a significant catalyst for market expansion, reflecting the increasing focus on innovative therapeutic approaches to alleviate cancer pain and improve patient outcomes.

The Cancer Pain market is further driven by the escalating prevalence of cancer worldwide. As reported by the American Cancer Society, the United States alone witnessed nearly 1.8 million new cancer cases and over 600,000 cancer-related deaths in 2020. Additionally, the International Agency for Research on Cancer highlighted approximately 1,065,960 new cases of colorectal cancer reported globally in the same year. The aging population, particularly susceptible to various cancers such as lung, bladder, renal, and melanoma, due to aging and genetic mutations, further contributes to the market's expansion.

The increase in healthcare expenditure and investments in research and development by healthcare companies play a pivotal role in fueling market growth. In 2019, the National Health Expenditure (NHE) in the United States reached a staggering $3.8 trillion, accounting for 17.7% of the country's GDP. This surge in healthcare spending underscores the priority placed on addressing cancer-related challenges, including pain management.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Real-Time Data Updates:
  • Competitor Benchmarking
  • Market Trends Heatmap
  • Custom Research Queries
  • Market Sentiment Analysis
  • Demographic and Geographic Insights

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The aging population is a significant driver of the Cancer Pain market due to higher incidence of cancer

People are more likely to have cancer as they age, and people over 65 are more likely to get several types of cancer. For instance, the World Health Organization projects that one-sixth of the world's population will be 60 years of age or older by 2030.As a result, there is a greater prevalence of cancer-related pain due to the global increase in life expectancy and aging population. Furthermore, chronic conditions like diabetes, arthritis, and cardiovascular disease frequently develop with aging, increasing a person's risk of developing cancer or exacerbating pre-existing symptoms. The need for efficient pain management treatments in the Cancer Pain market is further fueled by these comorbidities, which increase the burden of pain in older persons.

The high cost of cancer treatment, including pain management, poses a significant restraint on the market

Pain management may raise the overall cost of treatment, particularly for cancer medicines like chemotherapy, radiation therapy, and targeted therapies, which can be costly. Financial difficulties are a common problem for cancer patients because of their treatment-related out-of-pocket costs, co-pays, and medical bills. High treatment costs may lead to financial toxicity, where patients may forgo or delay seeking pain management due to affordability issues, impacting their quality of life.

The increasing availability of drugs for pain management creates a significant opportunity in the Cancer Pain market

Pharmaceutical companies are always developing and releasing novel analgesic medications with various delivery systems, formulations, and mechanisms of action. The array of treatment options available for the management of cancer pain is growing due to advancements in drug discovery, including the discovery of novel targets and pathways implicated in pain signaling. Concerns of opioid abuse and addiction are also addressed by the development of non-opioid analgesics and adjuvant therapies, which provide alternatives to conventional opioid-based pain management. These developments allow medical professionals more alternatives to customize pain management plans to the unique requirements and preferences of each patient, which eventually improves results and patient satisfaction.

Competitive Landscape

Pharmaceutical companies are in intense competition to develop and offer novel pain management therapies, which defines the competitive landscape of the Cancer Pain industry. Pharmaceutical giants like Pfizer Inc., Teva Pharmaceutical Industries Limited, and Hisamitsu Pharmaceutical Co. Inc. are a few of the major players in the market. In order to obtain a competitive advantage, these businesses compete through tactics like product innovation, strategic alliances, acquisitions, and global growth. Additionally, the market is witnessing the emergence of biotechnology firms and startups focusing on novel approaches to pain management, including targeted therapies and non-opioid alternatives.

In 2022, witnessed Parker Laboratories Inc. expanding its analgesics line with the introduction of Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Therapy Cream under its HelixTM brand, complementing its existing range of pain relief creams and medical contact media.

In 2023, the FDA approval of Gamida Cell’s allogeneic cell therapy Omisirge, promising to broaden access to stem cell transplants and enhance patient outcomes, marking a significant milestone in the field of cell therapy and providing hope for patients requiring transplantation.

The key players in the global Cancer Pain market include - Teva Pharmaceutical Industries Ltd. (Israel), Orexo AB (Sweden), Aoxing Pharmaceutical Company Inc. (U.S.), Grünenthal Pharma GmbH & Co. KG (Germany), BioDelivery Sciences International Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan), CK Life Sciences (Wex Pharmaceuticals) (Hong Kong), Mundipharma International Ltd. (UK), Hisamitsu Pharmaceutical Co.Inc. (Japan), Pfizer Inc. (U.S.) among others.

Recent Market Developments

FDA Grants Approvals for Key Cancer Treatments

  • In 2024, the FDA granted approvals for three significant cancer treatments, marking a milestone in cancer management and care in January 2024. Pembrolizumab (Keytruda), external beam radiotherapy, and concurrent chemotherapy received approval for treating cervical cancer, providing new options for patients with this challenging condition.

Radformation Partners with Icon Group to Transform Cancer Care

  • In February 2024, Radformation, a leading provider of radiation oncology software solutions, announced a strategic partnership with Icon Group (Icon), a global leader in comprehensive cancer care. This collaboration brings together the expertise of both organizations to revolutionize cancer care through innovative workflows and advanced software solutions.

Quibim Collaborates with Merck KGaA to Advance Cancer Diagnostics

  • In January 2024, saw Quibim, a company dedicated to translating imaging data into actionable insights for cancer diagnosis and treatment response, teaming up with Merck KGaA. This collaboration aims to advance high-level imaging-based diagnostics for precise medication strategies.

The global Cancer Pain market can be categorized as Drug Type, Disease Indication, and Region.

Parameter Details
Segments Covered

By Drug Type

  • Opioids
    • Morphine
    • Fentanyl
    • Other Opioids
  • Non-Opioids
    • Acetaminophen
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Nerve Blockers

By Disease Indication

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Other Disease Indications

By Region

  • North America
    • U.S.
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Orexo AB (Sweden)
  • Aoxing Pharmaceutical Company Inc. (U.S.)
  • Grünenthal Pharma GmbH & Co. KG (Germany)
  • BioDelivery Sciences International Inc. (U.S.)
  • Daiichi Sankyo Co. Ltd. (Japan)
  • CK Life Sciences (Wex Pharmaceuticals) (Hong Kong)
  • Mundipharma International Ltd. (UK)
  • Hisamitsu Pharmaceutical Co.Inc. (Japan)
  • Pfizer Inc. (U.S.)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis
Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Explore purchase options

FAQ
Frequently Asked Question
  • The global Cancer Pain valued at USD 7.39 Billion in 2023 and is expected to reach USD 11.86 Billion in 2032 growing at a CAGR of 5.4%.

  • The prominent players in the market are Teva Pharmaceutical Industries Ltd. (Israel), Orexo AB (Sweden), Aoxing Pharmaceutical Company Inc. (U.S.), Grünenthal Pharma GmbH & Co. KG (Germany), BioDelivery Sciences International Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan), CK Life Sciences (Wex Pharmaceuticals) (Hong Kong), Mundipharma International Ltd. (UK), Hisamitsu Pharmaceutical Co.Inc. (Japan), Pfizer Inc. (U.S.).

  • The market is project to grow at a CAGR of 5.4% between 2024 and 2032.

  • The driving factors of the Cancer Pain include

  • North America was the leading regional segment of the Cancer Pain in 2023.